Wedbush Maintains Outperform on Kiniksa Pharmaceuticals, Raises Price Target to $99
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice Target
Wedbush analyst David Nierengarten maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Outperform and raises the price target from $72 to $99.
Wedbush analyst David Nierengarten maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Outperform and raises the price target from $72 to $99.